Phase II study of motesanib in Japanese patients with advanced gastrointestinal stromal tumors with prior exposure to imatinib mesylate

Cancer Chemotherapy and Pharmacology

Volumn 65, Issue 5, 2010, Pages 961-967

  Sawaki, Akira ^a   Yamada, Yasuhide ^b   Komatsu, Yoshito ^c   Kanda, Tatsuo ^d   Doi, Toshihiko ^e   Koseki, Masato ^f   Baba, Hideo ^g   Sun, Yu Nien ^h   Murakami, Koji ⁱ   Nishida, Toshirou ^j  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

^c HOKKAIDO UNIVERSITY HOSPITAL   (Japan)

^d NIIGATA UNIVERSITY MEDICAL AND DENTAL HOSPITAL   (Japan)

^e NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^f NATIONAL HOSPITAL ORGANIZATION   (Japan)

^g KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^h AMGEN INC   (United States)

ⁱ DOKKYO MEDICAL UNIVERSITY   (Japan)

^j OSAKA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

Angiogenesis inhibitor; Gastrointestinal stromal tumor (GIST); Motesanib

Indexed keywords

AMG; IMATINIB; MOTESANIB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTICLE; BODY WEIGHT; CANCER GROWTH; CANCER RELAPSE; CANCER SURVIVAL; CHOLECYSTITIS; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; DYSPHONIA; FATIGUE; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL STROMAL TUMOR; HEADACHE; HUMAN; HYPERTENSION; HYPERURICEMIA; JAPANESE; MALE; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; SINGLE DRUG DOSE; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; DRUG RESISTANCE, NEOPLASM; DRUG TOLERANCE; FEMALE; GASTROINTESTINAL STROMAL TUMORS; HUMANS; INDOLES; JAPAN; MALE; MIDDLE AGED; NIACINAMIDE; PIPERAZINES; PYRIMIDINES; TREATMENT OUTCOME;

EID: 77649186041     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-009-1103-9     Document Type: Article

References (15)

1. RP DeMatteo MC Heinrich WM El-Rifai GD Demetri 2002 Clinical management of gastrointestinal stromal tumors: before and after STI-571 Hum Pathol 33 466 477 10.1053/hupa.2002.124122 1:CAS:528:DC%2BD38XlslCls7o%3D 12094371 (Pubitemid 34747865)
2. RP DeMatteo JJ Lewis D Leung SS Mudan JM Woodruff MF Brennan 2000 Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival Ann Surg 31 51 58 10.1097/00000658-200001000-00008 (Pubitemid 30043939)
3. S Hirota K Isozaki Y Moriyama, et al. 1998 Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors Science 279 577 580 10.1126/science.279.5350.577 1:CAS:528:DyaK1cXotVyhsw%3D%3D 9438854 (Pubitemid 28067289)
4. MC Heinrich CL Corless A Duensing, et al. 2003 PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 708 710 10.1126/science.1079666 1:CAS:528:DC%2BD3sXntFWitQ%3D%3D 12522257 (Pubitemid 36159485)
5. H Joensuu PJ Roberts M Sarlomo-Rikala, et al. 2001 Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor N Engl J Med 344 1052 1056 10.1056/NEJM200104053441404 1:STN:280:DC%2BD3M3gvVekuw%3D%3D 11287975 (Pubitemid 32267975)
6. GD Demetri M von Mehren CD Blanke, et al. 2002 Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors N Engl J Med 347 472 480 10.1056/NEJMoa020461 1:CAS:528:DC%2BD38XmtV2nt7s%3D 12181401 (Pubitemid 34879334)
7. J Verweij PG Casali J Zalcberg, et al. 2004 Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial Lancet 364 1127 1134 10.1016/S0140-6736(04)17098-0 1:CAS:528: DC%2BD2cXnvVOiu7o%3D 15451219 (Pubitemid 39296599)
8. M Van Glabbeke J Verweij PG Casali, et al. 2005 Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study J Clin Oncol 23 5795 5804 10.1200/JCO.2005.11.601 16110036 (Pubitemid 46300176)
9. GD Demetri AT van Oosterom CR Garrett, et al. 2006 Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 1329 1338 10.1016/S0140-6736(06)69446-4 1:CAS:528:DC%2BD28XhtVOrtL%2FL 17046465 (Pubitemid 44528723)
10. Collett D (1991) Modelling binary data. Chapman & Hall/CRC, London
11. SAS Institute Inc. (1999) SAS/STAT user's guide, version 8. Cary, NC
12. LS Rosen R Kurzrock M Mulay, et al. 2007 Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors J Clin Oncol 25 2369 2376 10.1200/JCO.2006.07.8170 1:CAS:528:DC%2BD2sXns1KmtL0%3D 17557949 (Pubitemid 46999207)
13. H Choi C Charnsangavej SC Faria, et al. 2004 CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings Am J Roentgenol 183 1619 1628
14. H Choi C Charnsangavej SC Faria, et al. 2007 Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria J Clin Oncol 25 1753 1759 10.1200/JCO.2006.07.3049 17470865 (Pubitemid 46797957)
15. RS Benjamin H Choi HA Macapinlac, et al. 2007 We should desist using RECIST, at least in GIST J Clin Oncol 25 1760 1764 10.1200/JCO.2006.07.3411 17470866 (Pubitemid 46797958)